Khiron Life Sciences Corp. (TSXV:KHRN) was featured in a speculative buy report by Canaccord Genuity, an independent full-service financial services firm. The basis for the report was based on Khiron’s first mover advantage and the emerging legalized cannabis markets in Latin America.

Khiron operates out of Colombia, which offers optimal growing conditions, cost advantages, liberal prescribing regulations and a medical cannabis market comprised of approximately 700,000 patients. The report concluded, that the Latin American cannabis market has a potential to make $8 to $9 billion annually. The report highlighted Khiron’s facilities in Colombia, which will be able to produce approximately 16,900 kilograms of cannabis per year and will be able to service approximately 100,000 patients. The company is expecting its first harvest in late 2018 and expects sales to commence in early 2019.


The report also touched on Khiron’s established medical cannabis patient network of approximately 400,000 patients. Their patient base has been developed through their education platform and their strategic alliances with 3,000 doctors. The company is also in the process of closing an acquisition for the ILANS clinics, which could bring an additional 100,000 patients to its portfolio. The first clinic is expected to be operational by the end of 2018 depending on the closing of the acquisition.

These two factors, among others, provided the basis for the report’s $3 speculative buy rating.

 

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation.

Source: canaccordgenuity.bluematrix.com

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less